ESSA PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.08 USD | -0.65% |
|
-3.80% | -7.88% |
| 06/03 | Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call | |
| 06/03 | Norway's wealth fund pushes for more women on emerging market company boards | RE |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 368M 270M 22.51B |
|---|---|---|---|---|---|
| Net income 2024 * | -48M -35.17M -2.93B | Net income 2025 * | -78M -57.16M -4.77B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-7.66
x | P/E ratio 2025 * |
-5.45
x | Employees | 50 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.72% |
More Fundamentals
* Assessed data
More news
Latest transcript on ESSA Pharma Inc.
More recommendations
More press releases
| 1 day | -0.65% | ||
| 1 week | -3.80% | ||
| Current month | -28.39% | ||
| 1 month | -28.39% | ||
| 3 months | -21.95% | ||
| 6 months | +37.56% | ||
| Current year | -7.88% |
1 week
5.71
7.25
1 month
5.718.68
Current year
5.7011.67
1 year
2.5611.67
3 years
1.4036.00
5 years
1.4036.00
10 years
1.40245.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Parkinson
CEO | Chief Executive Officer | 73 | 24/15/24 |
David Wood
DFI | Director of Finance/CFO | 66 | 01/13/01 |
Peter Virsik
COO | Chief Operating Officer | - | 01/16/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 05/15/05 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 31/19/31 |
Richard Glickman
CHM | Chairman | 65 | 01/10/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 6.08 | -0.65% | 178,467 |
| 25/24/25 | 6.12 | -2.08% | 64,770 |
| 24/24/24 | 6.25 | -2.34% | 41,308 |
| 23/24/23 | 6.4 | 0.00% | 130,486 |
| 22/24/22 | 6.4 | +1.27% | 122,377 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Calendar
07/05/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.323
CAD
Average target price
27.08
CAD
Spread / Average Target
+225.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.88% | 269M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- EPIX Stock
